biostudies-literatureUnknown121(12)Darlix AThis work was supported by R&amp;D UNICANCER. The ESME MBC database is supported by an industrial consortium<h4>Background</h4>Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.<h4>Methods</h4>The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan-Meier method).<h4>Results</h4>CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2-/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR- (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8-92.0). The median CNSMBritish journal of cancer991-1000https://www.ebi.ac.uk/biostudies/studies/S-EPMC6964671biostudies-literatureImpact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.PMC6964671Chevrot MLevy CLouvel GPasquier DFerrero JMUwer LBrain ERobain MLeheurteur MCottu PDarlix ACampone MLecouillard IAugereau PGoncalves ADalenc FDieras VJacot WFraisse JDebled MMouret-Reynier MAFumet JDBachelot TPetit TJouannaud CDelaloge SfalseImpact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.<h4>Background</h4>Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.<h4>Methods</h4>The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan-Meier method).<h4>Results</h4>CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2-/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR- (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8-92.0). The median CNSM2019-01-01T00:00:00Z2019 Dec2026-05-07T02:55:27.67Z2020-11-19T11:38:10ZS-EPMC69646713171968410.1038/s41416-019-0619-y